Product Datasheet  
Bcl10 Antibody  
Catalog Number: 49095  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot#:O95999
  • Form of Antibody：  
  • 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
  • Storage：  
  • Store at -20˚C
  • Immunogen：  
  • recombinant protein
  • reactivity：  
  • Hu
  • appl_detail：  

  • WB: 1:1,000
    IHC: 1:50-1:200
    ICC: 1:50-1:200

  • other_names：  
  • AI132454 antibody
    B cell CLL/lymphoma 10 antibody
    B cell lymphoma/leukemia10 antibody
    B-cell CLL/lymphoma 10 antibody
    B-cell leukemia/lymphoma 10 antibody
    B-cell lymphoma/leukemia 10 antibody
    Bcl 10 antibody
    Bcl-10 antib
  • Purification：  
  • ProA affinity purified
  • Specificity：  
  • Applications：  
  • WB, ICC/IF, IHC, IP
  • Background：  

  • Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types. Bcl10 is homologous to the equine herpesvirus-2 E10 gene and, like E10, it contains an N-terminal caspase recruitment domain (CARD). Expression of Bcl10 has been shown to induce NFκB activation in a NIK-dependent pathway, and research indicates that the CARD domain is essential for this activation; although in a separate study, Bcl10 by itself did not induce JNK or NFκB activation. Overexpression of Bcl10 has been shown to induce apoptosis in a manner dependent on CARD-mediated oligomerization. Bcl10 has also been shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.




 
© Signalway Biotechnology All Rights Reserved.